Atopic Dermatitis
Top news of July: Permanent makeup, FDA approvals, tattoos, more
Healio has compiled July’s most-read news in dermatology.
Imaging device tracks skin improvement following prebiotic treatment in skin of color
A new imaging device effectively monitored skin texture changes in patients with skin of color with atopic dermatitis and xerosis following a prebiotic skincare regimen, according to a study.
Recently published results highlight nemolizumab’s efficacy, safety in atopic dermatitis
New results evaluating the efficacy and safety of nemolizumab for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis were published in The Lancet, Galderma announced in a press release.
American Skin Association research grant recipients to target psoriasis, vitiligo, more
The American Skin Association has announced the recipients of its 2024 research grants for skin cancer and diseases, according to a press release.
Baricitinib, dupilumab see comparable real-world results in atopic dermatitis
Responses to baricitinib and dupilumab were notable and similar among patients with moderate to severe atopic dermatitis in a real-world setting, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
UK health authority recommends Ebglyss for atopic dermatitis treatment in England
The National Institute for Health and Care Excellence has recommended Ebglyss for the treatment of moderate to severe atopic dermatitis in the National Health Service England, according to an Almirall press release.
‘Follow the science and follow your gut’ to make a change in medicine
Emma Guttman-Yassky, MD, PhD, lives her life in dichotomy. She’s a dermatologist and an immunologist; a researcher and a department chair; and her medical and research experience transcends the globe, from North America to Europe.
Enrollment completed in phase 2 trial of bempikibart for atopic dermatitis treatment
Enrollment has been completed in a phase 2 clinical trial for the evaluation of bempikibart as a treatment for adults with persistent, moderate to severe atopic dermatitis, Q32 Bio announced in a press release.
FDA approves Zoryve for atopic dermatitis in adults, children
The FDA has approved Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older, Arcutis announced in a press release.
FDA pens action letter in response to roflumilast cream 0.15% sNDA for atopic dermatitis
The FDA is working to finalize an action letter regarding Arcutis’ supplemental new drug application for roflumilast cream 0.15% indicated for atopic dermatitis, the company announced in a press release.